| |
Fig. 4. XHas2 loss-of-function phenotype during early myogenesis. Dorsal view of XHas2-Mo injected embryos at neurula stage analyzed for XmyoD (A), CA (B,B',D) and p27 (C) expression by whole-mount in situ hybridization. Notably, p27 expression appeared unaltered in primary neurons (arrow). (B′) Bisection of embryo shown in B. (D) Bisected XHas2-Mo injected embryo at stage 22 showing a reduced somite mass in the injected side. (E) Injected neurula stage embryo stained with PH3 antibody. (F) Injected embryo analyzed by a BrdU incorporation assay (light blue, X-gal staining). (G) Whole mount TUNEL staining in XHas2-Mo injected neurula stage embryo. (G′) Bisected neurula embryo showing the increased number of apoptotic cells in the presomitic mesoderm of the injected side (arrowheads). (H-I′) Lateral view at the level of trunk somitic region of XHas2-Mo injected embryos processed by TUNEL assay. (H,I) Control side of stage 24 (H) and stage 30 (I) embryos. (H′,I′) Injected side of the embryos shown in H and I. No apoptotic cells were found at these stages in both control and injected side of the embryos. (I′) In stage 30 embryos, physiological level of apoptosis was found in the telencephalon (arrow). |
